333,200 Shares in Omnicell, Inc. (NASDAQ:OMCL) Acquired by Oberweis Asset Management Inc.

Oberweis Asset Management Inc. bought a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 333,200 shares of the company's stock, valued at approximately $14,834,000. Oberweis Asset Management Inc. owned 0.72% of Omnicell as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its holdings in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after acquiring an additional 273 shares during the period. Summit Investment Advisors Inc. lifted its holdings in Omnicell by 6.9% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock valued at $213,000 after acquiring an additional 307 shares during the last quarter. Van ECK Associates Corp grew its position in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after acquiring an additional 315 shares during the period. First Horizon Advisors Inc. lifted its stake in shares of Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after purchasing an additional 355 shares during the last quarter. Finally, Redmond Asset Management LLC grew its holdings in shares of Omnicell by 0.3% during the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company's stock worth $5,396,000 after purchasing an additional 371 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Stock Performance

Shares of Omnicell stock traded up $0.61 during trading hours on Tuesday, hitting $31.45. 95,192 shares of the company were exchanged, compared to its average volume of 534,541. The business has a 50-day moving average of $34.14 and a 200-day moving average of $40.76. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 116.46, a P/E/G ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Wells Fargo & Company dropped their target price on shares of Omnicell from $40.00 to $38.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Benchmark reiterated a "buy" rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. JPMorgan Chase & Co. reduced their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, March 20th. Bank of America reduced their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. Finally, StockNews.com raised Omnicell from a "hold" rating to a "buy" rating in a research report on Friday. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $50.67.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.